Brokerages expect that United Therapeutics Co. (NASDAQ:UTHR) will report sales of $331.78 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for United Therapeutics’ earnings, with the lowest sales estimate coming in at $316.71 million and the highest estimate coming in at $340.00 million. United Therapeutics posted sales of $444.50 million in the same quarter last year, which suggests a negative year-over-year growth rate of 25.4%. The company is scheduled to announce its next quarterly earnings results on Wednesday, August 7th.
According to Zacks, analysts expect that United Therapeutics will report full year sales of $1.32 billion for the current year, with estimates ranging from $1.27 billion to $1.36 billion. For the next year, analysts anticipate that the firm will post sales of $1.28 billion, with estimates ranging from $1.15 billion to $1.50 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($11.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.64 by ($13.96). The firm had revenue of $362.70 million for the quarter, compared to the consensus estimate of $335.72 million. United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. The company’s revenue was down 6.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.76 EPS.
Several equities research analysts have recently commented on UTHR shares. TheStreet upgraded United Therapeutics from a “c+” rating to a “b-” rating in a report on Monday, February 11th. BidaskClub downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 31st. Oppenheimer set a $160.00 price objective on United Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 26th. Wedbush set a $269.00 price objective on United Therapeutics and gave the company a “buy” rating in a report on Monday, April 8th. Finally, LADENBURG THALM/SH SH set a $124.00 target price on United Therapeutics and gave the company a “hold” rating in a research report on Thursday, February 28th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $132.89.
In related news, Director Christopher Patusky sold 3,370 shares of United Therapeutics stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $110.75, for a total transaction of $373,227.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 8.20% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of UTHR. Fort L.P. purchased a new position in United Therapeutics in the first quarter worth $25,000. Captrust Financial Advisors boosted its position in United Therapeutics by 384.9% in the fourth quarter. Captrust Financial Advisors now owns 257 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 204 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new position in United Therapeutics in the first quarter worth $29,000. Oregon Public Employees Retirement Fund boosted its position in United Therapeutics by 10,537.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,551,229 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 3,517,845 shares during the last quarter. Finally, First Mercantile Trust Co. boosted its position in United Therapeutics by 47.8% in the fourth quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 110 shares during the last quarter. 97.29% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ UTHR traded up $0.38 during midday trading on Monday, hitting $89.71. 14,373 shares of the stock traded hands, compared to its average volume of 436,571. The company has a market cap of $3.91 billion, a price-to-earnings ratio of 6.68 and a beta of 1.01. United Therapeutics has a one year low of $88.25 and a one year high of $130.00. The company has a quick ratio of 6.84, a current ratio of 7.19 and a debt-to-equity ratio of 0.45.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Recommended Story: Net Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.